Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).
Biomarker and diagnostic research for lymphoproliferative syndrome has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 2 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT01821781](https://clinicaltrials.gov/study/NCT01821781) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 7:14 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Immune Disorder HSCT Protocol
PHASE2 |
Washington University School of Medicine |
UNKNOWN |
[NCT00001350](https://clinicaltrials.gov/study/NCT00001350) | Study of Autoimmune Lymphoproliferative Syndrome (ALPS) | — | National Institute of Allergy and Infectious Diseases (NIAID) | RECRUITING |
[NCT04902807](https://clinicaltrials.gov/study/NCT04902807) | Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation | — | Institut National de la Santé Et de la Recherche Médicale, France | RECRUITING |
[NCT06781437](https://clinicaltrials.gov/study/NCT06781437) | Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH) | — | IRCCS Azienda Ospedaliero-Universitaria di Bologna | UNKNOWN |
[NCT06730126](https://clinicaltrials.gov/study/NCT06730126) | Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients | PHASE2 | National Institute of Allergy and Infectious Diseases (NIAID) | RECRUITING |
221 publications have been identified in PubMed for lymphoproliferative syndrome. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 78 | 35% |
Research summaries | 53 | 24% |
Laboratory research | 29 | 13% |
Disease patterns and progression | 22 | 10% |
Testing and diagnosis research | 12 | 5% |
Clinical study results | 11 | 5% |
Other research | 9 | 4% |
New treatment approaches | 7 | 3% |
Aydin S (2026). [PMID: 41760118](https://pubmed.ncbi.nlm.nih.gov/41760118/). *Klinische Padiatrie*. [Case Report / Case Series]
Hua G (2026). [PMID: 41713893](https://pubmed.ncbi.nlm.nih.gov/41713893/). *BMJ Case Rep*. [Review / Meta-Analysis]
Cornago J (2026). [PMID: 42056024](https://pubmed.ncbi.nlm.nih.gov/42056024/). *Br J Haematol*. [Clinical Trial Publication]
Justiz Vaillant AA (2026). [PMID: 30725847](https://pubmed.ncbi.nlm.nih.gov/30725847/). *Unknown Journal*. [Other]
Wakatsuki R (2026). [PMID: 41556306](https://pubmed.ncbi.nlm.nih.gov/41556306/). *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. [Diagnostic / Biomarker]
Samant H (2026). [PMID: 30020621](https://pubmed.ncbi.nlm.nih.gov/30020621/). *Unknown Journal*. [Diagnostic / Biomarker]
Shaikh H (2026). [PMID: 30085557](https://pubmed.ncbi.nlm.nih.gov/30085557/). *Unknown Journal*. [Other]
Pau A (2026). [PMID: 41751590](https://pubmed.ncbi.nlm.nih.gov/41751590/). *Genes*. [Gene Therapy / Novel Therapeutics]
Hakamifard A (2026). [PMID: 42183336](https://pubmed.ncbi.nlm.nih.gov/42183336/). *Case Rep Med*. [Case Report / Case Series]
Jiang HY (2026). [PMID: 41891350](https://pubmed.ncbi.nlm.nih.gov/41891350/). *J Cutan Med Surg*. [Case Report / Case Series]